MedicaidPrior AuthMedium impact
KMAP BULLETIN: Preferred Drug List Update
Kansas Medicaid (KanCare)·KS · Endocrinology, Family Medicine, Internal Medicine +1 more·Pharmacy
Effective date
Feb 1, 2024
We identified it
Jun 21, 2026
Summary
Kansas Medicaid (KMAP) updated their Preferred Drug List effective February 1, 2024, requiring prior authorization for 6 new medications including diabetes drugs (Fiasp, Metformin), while removing prior auth requirements for Lantus insulin products. This affects prescription billing and authorization workflows for Kansas Medicaid patients.
Action Required
Effective February 1, 2024: Update prior authorization workflow to require PA for Insulin Aspart (Fiasp PenFill) Cartridge, Metformin HCL 625mg, Methotrexate (Jylamvo), Sitagliptin (Zituvio), Tramadol HCL 25mg, and Valsartan Oral Solution (Labeler 72336) for Kansas Medicaid patients. Remove PA requirements for Insulin Glargine (Lantus) Vial and SoloStar Pen as of January 15, 2024. Clinical staff must obtain prior authorization before prescribing newly listed medications to avoid claim denials.